Study Assessing QBS72S For Treating Brain Metastases of Triple Negative Breast Cancer
Status:
Not yet recruiting
Trial end date:
2025-10-01
Target enrollment:
Participant gender:
Summary
This study will evaluate whether the chemotherapy agent QBS10072S,a.k.a. QBS72S, is effective
and safe as a treatment for two types of brain metastases from triple negative breast cancer.